RUNX1 and acute myeloid leukemia: The resulting chimeric protein termed AML-ETO retains the ability to bind RUNX1 target genes while exerting the transcription repression function of ETO, silencing RUNX1 genes contributing to the development of various hematopoietic cancers, most notably AML.